Veracyte, Inc.
VCYT
Rankning i aktier
#4423
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aktiekurs
$43.77
Senast synkroniserad: 2026-10-19
Marknadsvärde
$3.52B
Förändring (1 dag)
1.51%
Förändring (1 år)
19.43%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategori
Healthcare
EPS för Veracyte, Inc. (VCYT)
EPS per June 2026 TTM: $1.44
Enligt Veracyte, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $1.44. Vid slutet av 2023 hade bolaget ett EPS på $-1.02, en ökning jämfört med EPS från 2022 som var $-0.51.
EPS-historik för Veracyte, Inc. från 2011 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $1.44 | 350.00% |
| 2024 | $0.32 | -131.37% |
| 2023 | $-1.02 | 100.00% |
| 2022 | $-0.51 | -54.05% |
| 2021 | $-1.11 | 68.18% |
| 2020 | $-0.66 | 144.44% |
| 2019 | $-0.27 | -56.45% |
| 2018 | $-0.62 | -31.87% |
| 2017 | $-0.91 | -16.51% |
| 2016 | $-1.09 | -16.15% |
| 2015 | $-1.30 | -4.41% |
| 2014 | $-1.36 | -77.89% |
| 2013 | $-6.15 | 369.47% |
| 2012 | $-1.31 | 28.43% |
| 2011 | $-1.02 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $18.62 | 1,193.06% |
US
|
|
| $5.65 | 292.36% |
US
|
|
| $-1.36 | -194.44% |
US
|
|
| - | - |
CN
|
|
| $5.09 | 253.47% |
US
|
